Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

488 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, Ribeiro A, Mosseri V, Rubie H, Munzer C, Thomas C, Valteau-Couanet D, Auvrignon A, Plantaz D, Delattre O, Couturier J; Société Française des Cancers de l'Enfant (SFCE). Schleiermacher G, et al. Among authors: couturier j. Br J Cancer. 2007 Jul 16;97(2):238-46. doi: 10.1038/sj.bjc.6603820. Epub 2007 Jun 19. Br J Cancer. 2007. PMID: 17579628 Free PMC article.
Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P, Michon J. de Cremoux P, et al. Among authors: couturier j. Pediatr Blood Cancer. 2007 Mar;48(3):311-7. doi: 10.1002/pbc.20853. Pediatr Blood Cancer. 2007. PMID: 16609945
Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Janoueix-Lerosey I, et al. Among authors: couturier j. J Clin Oncol. 2009 Mar 1;27(7):1026-33. doi: 10.1200/JCO.2008.16.0630. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171713
Accumulation of segmental alterations determines progression in neuroblastoma.
Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O. Schleiermacher G, et al. Among authors: couturier j. J Clin Oncol. 2010 Jul 1;28(19):3122-30. doi: 10.1200/JCO.2009.26.7955. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516441
Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, Mosseri V, Thebaud E, Gambart M, Plantaz D, Marabelle A, Coze C, Rialland X, Fasola S, Lapouble E, Fréneaux P, Peuchmaur M, Michon J, Delattre O, Schleiermacher G. Guimier A, et al. Among authors: couturier j. PLoS One. 2014 Jul 11;9(7):e101990. doi: 10.1371/journal.pone.0101990. eCollection 2014. PLoS One. 2014. PMID: 25013904 Free PMC article.
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J. Schleiermacher G, et al. Among authors: couturier j. Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10. Br J Cancer. 2011. PMID: 22146831 Free PMC article.
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Rubie H, et al. Among authors: couturier j. J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172879 Clinical Trial.
Diagnostic and prognostic information obtained on fine-needle aspirates of primary neuroblastic tumors: Proposal for a cytology prognostic score.
Klijanienko J, Couturier J, Brisse H, Pierron G, Fréneaux P, Berger F, Maciorowski Z, Sastre-Garau X, Michon J, Schleiermacher G. Klijanienko J, et al. Among authors: couturier j. Cancer Cytopathol. 2011 Dec 25;119(6):411-23. doi: 10.1002/cncy.20173. Epub 2011 Jul 19. Cancer Cytopathol. 2011. PMID: 21774092 Free article.
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
Bourdeaut F, Grison C, Maurage CA, Laquerriere A, Vasiljevic A, Delisle MB, Michalak S, Figarella-Branger D, Doz F, Richer W, Pierron G, Miquel C, Delattre O, Couturier J. Bourdeaut F, et al. Among authors: couturier j. Cancer Genet. 2013 Apr;206(4):124-9. doi: 10.1016/j.cancergen.2013.02.003. Epub 2013 Apr 8. Cancer Genet. 2013. PMID: 23578955
488 results